<DOC>
	<DOCNO>NCT02001909</DOCNO>
	<brief_summary>To investigate effect neomycin pharmacokinetics ( PK ) regorafenib healthy male subject</brief_summary>
	<brief_title>Effect Neomycin Pharmacokinetics Regorafenib</brief_title>
	<detailed_description />
	<mesh_term>Neomycin</mesh_term>
	<criteria>Inclusion : Healthy male subject Age : 18 45 year ( inclusive ) first screen examination/visit Body mass index ( BMI ) : above/equal 18 30 kg / mÂ² Confirmation subject 's health insurance coverage prior first screen examination/visit Subjects enrol study must use adequate barrier birth control measure prior , course study , 3 month last administration regorafenib . An adequate contraception include use condom vasectomy . In addition , adequate birth control measure subject 's partner require , hormonal contraception implant combine oral contraceptive , certain intrauterine device , bilateral tubal ligation , hysterectomy . Exclusion : Known suspected hypersensitivity regorafenib and/or neomycin Any illness medical condition unstable could jeopardize safety subject compliance study Clinically significant illness within 30 day prior Day 1 , Period 1 . Regular use medicine time screening , include herbal supplement high dose vitamin Smoking ; however , former smoker stop smoke least 3 month first study drug administration may include Clinically relevant finding electrocardiogram ( ECG ) Clinically relevant finding complete physical examination Positive result hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) , human immune deficiency virus antibody ( antiHIV 1+2 ) screening . Positive urine drug screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>Neomycin</keyword>
	<keyword>Cancer</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
</DOC>